Prof. PeptideProf. Peptide

Berberine

Metabolic & Weight LossGut Health & Immunity

Last reviewed: May 24, 2026

Also Known As: Berberine HCl, berberine hydrochloride, dihydroberberine (DHB — a higher-bioavailability variant)

Supplement Class: Isoquinoline alkaloid (plant-derived AMPK activator)

Evidence Tier: Strong — Yin et al. 2008's head-to-head RCT against metformin in type 2 diabetes (comparable HbA1c reduction); Guo et al. 2021's meta-analysis of 46 RCTs (HbA1c mean difference -0.73 percentage points); Dong et al. 2012 and Lan et al. 2015's earlier meta-analyses (n=1,068 and n=2,569 respectively); dozens of human RCTs across metabolic syndrome endpoints; a mature AMPK pathway mechanism evidence base.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is berberine?

Berberine is a bioactive isoquinoline alkaloid extracted from several plants, including Berberis vulgaris (barberry), Coptis chinensis (goldenseal), and Phellodendron amurense. It has a documented history of use in traditional Chinese medicine, reported here as historical context, and has become one of the more-researched natural compounds for metabolic health. Berberine is reported to activate AMPK — the same cellular energy-sensing target metformin acts on — producing downstream effects on blood sugar regulation, hepatic gluconeogenesis, lipid metabolism, insulin sensitivity, and gut microbiome composition. Yin et al. 2008's head-to-head RCT against metformin reports a comparable glycemic effect at the 500 mg three-times-daily dose, and berberine is among the few natural compounds with prescription-comparable RCT evidence reviewed on this page. Berberine is also reported to modestly induce endogenous GLP-1 secretion, giving it a mechanistic overlap with injectable GLP-class peptides like semaglutide and tirzepatide.

Reported benefits:

  • HbA1c reduction comparable to metformin in a head-to-head trial (Yin et al. 2008)
  • Fasting and postprandial blood glucose reduction (Guo et al. 2021 and other meta-analyses)
  • Improved triglycerides, total cholesterol, and LDL — endpoints metformin is not reliably reported to affect
  • Modest weight loss in pooled trial data
  • Insulin sensitivity improvement; a PCOS application with reportedly comparable evidence to metformin
  • A small but statistically significant blood pressure reduction
  • Gut microbiome modulation (increased Akkermansia muciniphila, reduced inflammatory species in some studies)

Common dose: 500 mg three times daily with meals (1,500 mg/day total) — the Yin et al. 2008 reference protocol used across nearly all of the positive RCTs cited above. Twice-daily dosing (1,000 mg/day) is a reported tolerability compromise. A dihydroberberine alternative (100–200 mg twice daily) carries manufacturer claims of 5–10× plasma exposure at the lower dose. The reported short plasma half-life (3–4 hours) is why three-times-daily dosing is the trial standard.

Product-quality notes: Widely available over-the-counter. Quality is reported to vary — review the quality-markers checklist in the Product-quality considerations section below.

On this page
  1. 1.How does berberine work?
  2. 2.What does the evidence say berberine does?
  3. 3.How is berberine dosed in trials and on labels?
  4. 4.How berberine is taken
  5. 5.What does berberine stack with?
  6. 6.Side effects and interactions
  7. 7.What isn't established about berberine
  8. 8.Product-quality considerations
  9. 9.Berberine FAQ
  10. 10.References
  11. 11.Published Studies

How does berberine work?

Berberine's primary reported mechanism is AMPK activation, plus several downstream effects that converge on metabolic improvement. AMPK is the cellular energy-sensing pathway whose activation is discussed in the literature as mimicking the metabolic state of exercise and caloric restriction. Berberine is reported to activate AMPK by raising the AMP:ATP ratio in cells, triggering effects that include improved glucose uptake, suppressed hepatic glucose production, increased fat oxidation, and modulation of cholesterol synthesis.

  1. AMPK activation (the primary mechanism). Berberine is described in the literature as one of the strongest natural AMPK activators identified. AMPK activation is discussed as mimicking the metabolic effects of exercise and caloric restriction — improving glucose uptake into peripheral tissues, suppressing fatty acid and cholesterol synthesis in the liver, and supporting mitochondrial function. This is the same target metformin acts on, which is the mechanistic basis for the metformin comparison.
  2. Hepatic gluconeogenesis suppression. Berberine is reported to inhibit PEPCK and G6Pase, the two key enzymes responsible for glucose synthesis in the liver, reducing fasting blood glucose by limiting overnight hepatic glucose output — a mechanism described as similar to metformin's primary fasting-glucose action.
  3. Insulin sensitization. Berberine is reported to improve insulin signaling by enhancing GLUT4 glucose transporter translocation to the cell surface, supporting glucose uptake into muscle and fat cells — discussed as the mechanism behind the postprandial glucose improvements reported across multiple RCTs.
  4. Endogenous GLP-1 induction. Berberine is reported to modestly stimulate GLP-1 secretion from intestinal L cells — the same incretin hormone targeted by injectable drugs like semaglutide and tirzepatide. The effect is described as much smaller than direct receptor agonism, but is discussed as contributing to berberine's glycemic and appetite-related effects.
  5. Lipid metabolism modulation. Berberine is reported to upregulate LDL receptor expression in hepatocytes (the mechanism class statins target), increasing LDL cholesterol clearance from circulation. Kong et al. 2004 reports berberine works through a mechanism distinct from statins, via stabilization of LDL receptor messenger RNA. This dual mechanism is discussed as explaining why berberine reliably reduces total cholesterol and LDL alongside glycemic effects, distinguishing it from metformin.
  6. Gut microbiome modulation. Berberine is reported to reshape gut bacterial composition — increasing species such as Akkermansia muciniphila and reducing inflammatory phenotypes in some studies. This is discussed in the literature as a modern research frontier that may explain some of berberine's systemic anti-inflammatory and metabolic actions beyond direct AMPK or hepatic effects.

What does the evidence say berberine does?

Berberine has one of the deeper natural-compound evidence bases for metabolic intervention. The strongest evidence is in type 2 diabetes, including head-to-head data against metformin; the next-strongest is dyslipidemia; meaningful evidence exists for blood pressure, weight loss, gut microbiome effects, and PCOS.

  1. Type 2 diabetes glycemic control (Strong). Yin et al. 2008's head-to-head RCT against metformin and Guo et al. 2021's meta-analysis (46 RCTs) anchor this evidence. Guo et al. reports a mean HbA1c reduction of 0.73 percentage points versus control; Dong et al. 2012's earlier meta-analysis (14 RCTs, n=1,068) reports a similar magnitude.
  2. Dyslipidemia (Strong). Zhang et al. 2008 (n=116) and Lan et al. 2015's meta-analysis (n=2,569) report significant reductions in triglycerides, total cholesterol, and LDL. This dual glycemic-and-lipid effect is discussed in the literature as distinguishing berberine from metformin, which is not reliably reported to affect lipids.
  3. Blood pressure (Moderate). Lan et al. 2015's meta-analysis reports small but statistically significant reductions in systolic and diastolic blood pressure. The mechanism discussed is multifactorial — endothelial nitric oxide production, mild vasodilation, and improved insulin sensitivity.
  4. Weight loss (Moderate). Pooled meta-analyses report modest weight loss over roughly 12 weeks across heterogeneous protocols, meaningfully better than placebo but well below the magnitude reported for GLP-1 receptor agonists. The mechanism discussed is improved insulin sensitivity, AMPK-driven fat oxidation, and gut microbiome shifts.
  5. Polycystic ovary syndrome / PCOS (Moderate-Strong). Multiple RCTs in PCOS populations report improved insulin sensitivity, lipid profile, and menstrual regularity with berberine; some trials compare berberine to metformin in PCOS specifically with reportedly comparable results.
  6. Gut microbiome (Emerging-Moderate). Animal and human stool-sample studies report specific bacterial composition shifts (increased Akkermansia muciniphila, decreased opportunistic pathogens). The clinical implications of these shifts are still being characterized in the literature.
  7. NAFLD / fatty liver (Moderate). Several RCTs report reduced hepatic fat content and improved liver enzymes (ALT, AST) with berberine in non-alcoholic fatty liver disease, with hepatic AMPK activation discussed as the proposed mechanism reducing de novo lipogenesis.

How is berberine dosed in trials and on labels?

The clinical-trial standard dose reported across the sources cited on this page is 500 mg three times daily with meals, totaling 1,500 mg/day. The three-times-daily schedule reflects berberine HCl's reported 3–4 hour plasma half-life, which single daily dosing would not adequately cover. Dihydroberberine (DHB) is reported to offer a longer effective duration at lower doses.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. Standard trial protocol. 500 mg three times daily with meals (1,500 mg/day total) — the Yin et al. 2008 protocol, used across nearly all of the positive RCTs cited above.
  2. Lower starting dose. 500 mg once daily with the largest meal is a pattern used for the first 1–2 weeks in some protocols, allowing GI adaptation before scaling to the full three-times-daily schedule.
  3. Twice-daily protocol. 500 mg twice daily (1,000 mg/day) is reported by some pooled analyses as producing roughly 75% of the full protocol's effect size — a reasonable pattern if three-times-daily dosing is logistically difficult.
  4. Dihydroberberine (DHB) alternative. 100–200 mg twice daily — a higher-bioavailability variant with manufacturer-claimed 5–10× plasma exposure at equivalent doses, though head-to-head RCT data versus standard berberine HCl is limited in the literature reviewed.
  5. PCOS protocol. The same 500 mg three-times-daily standard dose, typically continued for 3–6 months in the trials reviewed, with periodic reassessment of insulin sensitivity and menstrual cycle markers.

Reported timeline: fasting glucose changes appear within 2–4 weeks in the trials reviewed. HbA1c changes were measured over 8–12 weeks (the 90-day glycation timeline). Lipid effects were reported at 4–8 weeks. Most clinical evidence reviewed for this page uses a 3-month minimum trial duration.

Bioavailability note. Berberine HCl has poor oral absolute bioavailability (roughly 0.5%) — most of an oral dose acts locally in the gut or is rapidly cleared. This is discussed in the literature as the reason dose frequency matters (three-times-daily maintains coverage), why GI side effects are common (high local concentration), and why dihydroberberine exists as a higher-absorbing alternative.

Label math. Products vary in whether they specify "berberine HCl" content explicitly (typically 500 mg) versus a proprietary blend combining berberine with cinnamon, chromium, or other ingredients that obscure the actual berberine dose.

How berberine is taken

Berberine is taken orally as a capsule. Because its mechanism depends on gut-meal interaction, food timing is reported as a meaningful practical factor. The table below reports what the cited trials and labels describe.

AspectReported
FrequencyThree times daily with meals in the standard trial protocol; twice daily as a reported tolerability compromise; dihydroberberine is marketed for once- or twice-daily dosing.
Time of dayDistributed across meals in the trials reviewed, aligned with morning, midday, and evening meals to target postprandial glucose excursions.
FoodWith meals — both for GI tolerance and to target meal-related glucose excursions, per the trial protocols. Empty-stomach dosing is reported to amplify GI side effects.
FormStandard capsule is the form used in the cited trials. Dihydroberberine is marketed for GI-sensitive users or those wanting fewer daily doses. Phytosome-complex products claim improved absorption, but RCT evidence for these formulations is limited in the literature reviewed.
Standardization markerLabels vary in whether 97%+ berberine HCl content is disclosed per capsule, versus a proprietary blend obscuring the actual berberine dose.
CyclingNo cycling protocol appears in the cited trials for the compound itself.

What does berberine stack with?

Berberine is discussed alongside the GLP-class peptide cluster (where it shares mechanistic overlap), other metabolic supplements working on complementary pathways, and lifestyle interventions that amplify AMPK activation.

With peptides

The natural peptide connections for berberine are the GLP-class incretin agonists. Semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GLP-1/GIP dual agonist) work via direct receptor activation; retatrutide extends to triple GLP-1/GIP/glucagon agonism. Berberine is reported to modestly induce endogenous GLP-1 secretion and activate AMPK — different pathways targeting overlapping metabolic endpoints. The combined hypoglycemic effect from stacking berberine with any GLP peptide is reported as a real consideration, particularly for people on background insulin or sulfonylureas — glucose monitoring is standard guidance. Also relevant: cagrilintide (an amylin analog) and cagrisema (a cagrilintide-plus-semaglutide combination), where the same monitoring considerations apply. Clinician coordination is standard guidance for any GLP-class stack.

With supplements

  1. Alpha lipoic acid — a reported effect on insulin sensitivity and oxidative stress via a different mechanism than berberine.
  2. Chromium — a cofactor for insulin receptor function, with a modest standalone reported effect on insulin sensitivity.
  3. Magnesium — an insulin signaling cofactor; deficiency is reported as widespread and contributing to insulin resistance.
  4. Green tea extract — EGCG is reported to modestly activate AMPK via a different pathway than berberine.
  5. Fish oil — an independent reported triglyceride-lowering pathway.
  6. Milk thistle / silymarin — discussed in the literature as hepatic support during long-term berberine use, particularly for users with elevated liver enzymes.

With lifestyle factors

  1. Meal-timed dosing. Dosing with the three largest meals is the pattern in the cited trials, targeting postprandial glucose blunting as one of the larger acute effects.
  2. Dietary carbohydrate load. Berberine's glycemic effect is reported as related to the carbohydrate load it's offsetting.
  3. Exercise. AMPK is the same target both berberine and exercise activate; the two are discussed as additive on metabolic endpoints in the research literature.
  4. Time-restricted eating. Compressing meal-related glucose load into a shorter window is discussed as amplifying berberine's per-meal blunting effect.
  5. Sleep. Insulin sensitivity is reported as strongly sleep-dependent; the literature does not describe berberine as compensating for chronic sleep deficit.

Side effects and interactions

Berberine's safety profile in published trials is generally favorable, with no serious adverse event signal reported across the meta-analyzed corpus cited on this page. The main considerations reported are GI side effects (common during the first 2–4 weeks), drug-drug interactions via CYP3A4 inhibition, and additive hypoglycemia risk when combined with diabetes medications. Pregnancy is a clear contraindication.

Common (mostly first-month transient)

  1. Diarrhea, loose stools, or constipation — reported most commonly during the first 2–4 weeks, improving with continued use in the trials reviewed.
  2. Nausea or stomach upset — reported particularly on an empty stomach.
  3. Bloating or gas — reported as typically transient, related to gut microbiome shifts in the first month.
  4. A bitter or metallic taste is reported with non-capsule forms (troches, powders).
  5. Hypoglycemia-related fatigue or shakiness — reported in users combining berberine with insulin or sulfonylureas; glucose monitoring is standard guidance.

Watch-list (less common, longer-term)

  1. Mild elevation in liver enzymes (ALT, AST) — reported in a minority of users on long-term, high-dose protocols; periodic liver-panel checks are standard guidance for use beyond 6 months.
  2. Possible hypotension in users on antihypertensive medication — a combined BP effect is reported to potentially produce orthostatic symptoms.
  3. Reduced or altered absorption of co-administered drugs via CYP3A4 inhibition — separating dosing of narrow-therapeutic-window drugs by 2+ hours is standard guidance.

Contraindications

  1. Pregnancy and breastfeeding — berberine is reported to cross the placenta and can cause kernicterus (bilirubin-related brain injury) in newborns, a documented contraindication.
  2. Infants — the same kernicterus risk applies.
  3. Active liver disease — berberine is reported to add to hepatic metabolic load; clinician supervision is standard guidance for any existing liver pathology.

Drug and supplement interactions

  1. CYP3A4 substrate drugs (statins, calcium channel blockers, many psychiatric drugs, some immunosuppressants including cyclosporine) — berberine is reported to inhibit CYP3A4, increasing plasma levels of these drugs; clinician coordination is standard guidance for chronic users of CYP3A4 substrates.
  2. Metformin — overlapping AMPK and hepatic gluconeogenesis suppression is reported to create combined hypoglycemia risk; clinician coordination is standard guidance.
  3. Insulin and sulfonylureas — additive hypoglycemia is a reported risk; glucose monitoring is standard guidance when adding berberine to background diabetes therapy.
  4. GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) — overlapping glycemic mechanisms are a reported consideration; glucose monitoring and awareness of compounded GI side effects is standard guidance.
  5. Antihypertensive medications — an additive BP-lowering effect is reported; watching for orthostatic symptoms is standard guidance.
  6. Anticoagulants (warfarin, DOACs) — a possible interaction via CYP and platelet effects is discussed; clinician coordination is standard guidance.
  7. Other AMPK activators (metformin, alpha-lipoic acid) — reported as generally additive and complementary, with total effect on glycemic markers as the relevant consideration.

What isn't established about berberine

Berberine's evidence base is unusually deep for a natural compound — dozens of RCTs, multiple meta-analyses, and prescription-comparable head-to-head data in type 2 diabetes. The remaining open questions are mostly about long-horizon safety, optimal forms, and the gut microbiome mechanism that is an active area of modern research.

Long-horizon safety in healthy users. Most safety data reviewed covers 3–6 month treatment courses in clinical populations (type 2 diabetes, dyslipidemia, PCOS). Continuous multi-year use in healthy users for metabolic-health purposes is less well-characterized in the sources reviewed — cumulative liver-enzyme effects, microbiome shifts, and long-horizon chronic AMPK activation are open questions.

Dihydroberberine vs standard form. DHB manufacturers claim 5–10× plasma exposure at equivalent doses, but direct head-to-head RCTs comparing DHB to standard berberine HCl on metabolic endpoints are limited in the literature reviewed. Whether DHB delivers equivalent clinical effects at the lower claimed doses is not formally established.

Gut microbiome mechanism. Berberine is reported to reshape bacterial composition, but the causal chain from microbiome shift to systemic metabolic improvement is still being characterized in the literature reviewed.

Cardiovascular outcomes. Berberine is reported to improve major cardiovascular risk factors (glucose, lipids, blood pressure, inflammation), but no large-scale cardiovascular outcomes trial establishing whether berberine reduces major adverse cardiovascular events appears in the sources reviewed for this page.

Optimal dose-response curve. The 500 mg three-times-daily protocol is the trial standard; whether higher total daily doses produce materially better outcomes has not been systematically tested in the sources reviewed.

Effect-size variability across studies. Reported effect sizes vary substantially across trials, particularly for weight loss and lipid endpoints. The directional signal is consistently positive across the meta-analyses reviewed; the magnitude variation likely reflects differences in population, dietary context, and protocol.

Population specificity. The strongest data reviewed is in newly diagnosed type 2 diabetes, established type 2 diabetes, dyslipidemia, and PCOS populations. The evidence base is thinner for healthy, non-metabolically-impaired adults using berberine for general metabolic-health purposes.

Product-quality considerations

Berberine is widely available over-the-counter. Quality is reported to vary, particularly around actual berberine HCl content versus proprietary-blend disclosure, third-party testing, and whether the product uses standard berberine HCl or dihydroberberine.

Quality markers reported in the category

  • Berberine HCl content explicitly disclosed per capsule — typically 500 mg in the trials cited above — rather than buried in a proprietary blend.
  • 97%+ standardization on berberine HCl content, or the matching disclosure for dihydroberberine variants.
  • Third-party testing — USP, NSF, or ConsumerLab certification for independent verification of label accuracy and contamination screening.
  • Proprietary "metabolic blend" products that mix berberine with cinnamon, chromium, or banaba leaf without disclosing the actual berberine dose don't allow independent evaluation.
  • Dihydroberberine products should specify actual DHB mg content for users pursuing the higher-bioavailability route.
  • Fresh manufacture date — a relevant check for any long-shelf supplement.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

Berberine FAQ

Is the comparison between berberine and metformin supported by trial data?

Yin et al. 2008 ran a 3-month trial comparing berberine 500 mg three times daily against metformin 500 mg three times daily in 36 newly diagnosed type 2 diabetes patients, reporting comparable HbA1c reduction (from 9.5% to roughly 7.5% in both groups) and similar improvements in fasting and postprandial glucose. Berberine additionally reduced triglycerides in that trial — an endpoint metformin is not reliably reported to affect. The mechanisms discussed in the literature overlap (AMPK activation, hepatic gluconeogenesis suppression, insulin sensitization) without being identical. This is a single small head-to-head trial (n=36), not a large-scale regulatory comparison, and switching from a prescribed diabetes medication is a decision for the prescribing clinician.

How does berberine compare mechanistically to semaglutide or tirzepatide?

These are different mechanism classes with different reported magnitudes of effect. Semaglutide and tirzepatide are GLP-1 and GLP-1/GIP receptor agonists that directly activate incretin receptors, reported to produce substantial weight loss in Phase 3 trials. Berberine is reported to modestly induce endogenous GLP-1 secretion from intestinal L cells (one of several mechanisms discussed in the literature) and is reported to produce smaller weight reduction in trials, typically in the low single-digit kilograms over 12 weeks. The two are discussed as targeting adjacent but non-identical pathways.

Can berberine be combined with semaglutide?

The literature discusses this combination with caveats. Berberine and semaglutide act on overlapping but non-identical pathways — berberine via AMPK and modest endogenous GLP-1 induction, semaglutide via direct GLP-1 receptor agonism. Adding berberine to a semaglutide protocol is discussed as potentially producing additive glucose-lowering and lipid effects, with a combined hypoglycemia risk reported as a real consideration, particularly for people on background insulin or sulfonylureas. Combined GI side effects (nausea, constipation, GI upset) are also reported as more burdensome than either agent alone. Clinician coordination is standard guidance for anyone on a GLP-class medication.

What's the difference between berberine HCl and dihydroberberine?

Berberine HCl is the form used in nearly all of the published clinical trials cited on this page. Its reported limitation is poor oral bioavailability (roughly 0.5% absolute) due to active intestinal efflux. Dihydroberberine (DHB) is a reduced form reported to absorb more efficiently, with manufacturer claims of 5–10× higher plasma exposure at equivalent doses; head-to-head clinical trials directly comparing DHB to standard berberine HCl on metabolic endpoints are limited in the literature reviewed for this page. The practical reported effect is that DHB allows a smaller dose with less reported GI burden, though the standard HCl form carries the deeper trial evidence base.

How long do blood-sugar changes take to appear in the cited trials?

Measurable changes in fasting glucose are reported to appear within 2–4 weeks of consistent dosing in the trials reviewed. HbA1c changes were measured over 8–12 weeks in the cited trials, consistent with HbA1c reflecting a roughly 90-day average of glycation. Lipid changes (triglycerides, total cholesterol) were generally reported at 4–8 weeks. Most of the clinical evidence reviewed for this page uses a 3-month minimum trial duration.

What does the evidence show for berberine and weight loss?

Meta-analyses report berberine producing modest weight loss — in the low single-digit kilograms over roughly 12 weeks across pooled trials — a smaller effect than reported for GLP-1 receptor agonist medications. The mechanism discussed in the literature is multifactorial: improved insulin sensitivity, AMPK-driven fat oxidation, and gut microbiome shifts. The literature discusses berberine as a metabolic-health intervention with weight loss as a downstream effect rather than a primary weight-loss agent.

Can berberine be combined with prescription metformin?

This combination is discussed in the literature as requiring clinician coordination rather than self-directed stacking. The mechanisms are reported to overlap substantially (both are AMPK activators, both are reported to suppress hepatic gluconeogenesis), so combining the two is discussed as potentially producing additive hypoglycemia — a particular consideration for people on background insulin or sulfonylureas.

Why is berberine typically dosed three times a day in trials?

Berberine HCl is reported to have a plasma half-life of roughly 3–4 hours, so a single daily dose would produce peak-and-trough exposure that doesn't cover the day. The 500 mg three-times-daily schedule used in Yin et al. 2008 and most subsequent trials cited on this page is designed to maintain more consistent plasma levels and align dosing with meal-related glucose excursions. Dihydroberberine's reported longer effective duration is discussed as allowing fewer daily doses for some users, though the TID schedule remains the protocol the bulk of the clinical evidence is based on for standard berberine HCl.

References

  1. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717. https://pubmed.ncbi.nlm.nih.gov/18442638/
  2. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559-2565. https://pubmed.ncbi.nlm.nih.gov/18397984/
  3. Guo Y, Zhang Y, et al. A meta-analysis of the effect of berberine in the treatment of type 2 diabetes. Oxid Med Cell Longev. 2021;2021:2074610. https://pubmed.ncbi.nlm.nih.gov/34956436/
  4. Dong H, Wang N, Zhao L, Lu F. The effect of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654. https://pubmed.ncbi.nlm.nih.gov/23118793/
  5. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81. https://pubmed.ncbi.nlm.nih.gov/25498346/
  6. Kong WJ, Vernieri C, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: a drug cloud (dCloud) effect to target multifactorial disorders. Pharmacol Ther. 2020;209:107496. https://pubmed.ncbi.nlm.nih.gov/32001311/
  7. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351. https://pubmed.ncbi.nlm.nih.gov/15531889/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Metabolism · 2008Open Access
Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus →

Yin J, Xing H, Ye J

A 3-month trial in 36 adults with newly diagnosed type 2 diabetes randomized to berberine 500 mg three times daily versus metformin 500 mg three times daily. Reports HbA1c fell from 9.5% to 7.5% (P<.01) with berberine, comparable to metformin, with similar reductions in fasting and postprandial glucose and a significant reduction in plasma triglycerides.

Journal of Clinical Endocrinology & Metabolism · 2008Open Access
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine →

Zhang Y, Li X, Zou D, et al.

A trial in 116 type 2 diabetic patients with dyslipidemia receiving 1 g/day berberine for 3 months. Reports significant reductions in fasting glucose, HbA1c, and triglycerides, with total cholesterol and LDL also significantly reduced — a dual glycemic-and-lipid effect distinguishing berberine from metformin, which is not reliably reported to affect lipids.

Oxidative Medicine and Cellular Longevity · 2021Open Access
A Meta-Analysis of the Effect of Berberine in the Treatment of Type 2 Diabetes →

Guo Y, Zhang Y, et al.

A meta-analysis of 46 RCTs of berberine in type 2 diabetes, applied alone or alongside standard diabetic therapy versus control. Reports a mean HbA1c reduction of -0.73 percentage points (95% CI -0.97 to -0.51) versus control, plus reductions in fasting plasma glucose and 2-hour postprandial glucose. The largest pooled meta-analysis of berberine's glycemic effect reviewed for this page.

Evidence-Based Complementary and Alternative Medicine · 2012Open Access
The Effect of Berberine on Blood Glucose in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis →

Dong H, Wang N, Zhao L, Lu F

A systematic review and meta-analysis of 14 RCTs (n=1,068) examining berberine's glycemic effects in type 2 diabetes. Reports berberine significantly reduced fasting blood glucose (weighted mean difference -0.71 mmol/L), HbA1c (-0.71%), and 2-hour postprandial blood glucose, with no serious adverse events reported across the included trials.

Journal of Ethnopharmacology · 2015Paywalled
Meta-Analysis of the Effect and Safety of Berberine in the Treatment of Type 2 Diabetes Mellitus, Hyperlipidemia and Hypertension →

Lan J, Zhao Y, Dong F, et al.

A meta-analysis of 27 RCTs (n=2,569) covering berberine's effects on type 2 diabetes, hyperlipidemia, and hypertension. Reports significant improvements in glycemic markers, the full lipid panel, and blood pressure, with mostly mild GI side effects and no serious adverse event signal across the pooled trials.

Pharmacology & Therapeutics · 2020Paywalled
Berberine in the Treatment of Metabolism-Related Chronic Diseases: A Drug Cloud (dCloud) Effect to Target Multifactorial Disorders →

Kong WJ, Vernieri C, Foiani M, Jiang JD

A review covering berberine's mechanism: inhibitory effects on mitochondrial enzymes activate LDL receptor, AMPK, and insulin receptor signaling, reducing plasma lipids and glucose; the review also describes pleiotropic antioxidant/anti-inflammatory effects and gut microbiota modification as contributing 'drug cloud' mechanisms beyond the single-target model.

AMPK ActivatorMetformin ComparisonBlood SugarGut MicrobiomePCOSDyslipidemia

Related Supplements

Alpha Lipoic AcidChromiumMagnesiumGreen Tea ExtractFish Oil

Comparisons

Berberine vs Metformin

Supplement brands

  • VitaTurbo: 1 product whose label lists it as the main active

We may earn commissions from peptide vendor affiliate links.

Have a question about Berberine? Send us an email